Clinical Trials Logo

Acne Keloidalis Nuchae clinical trials

View clinical trials related to Acne Keloidalis Nuchae.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05608499 Recruiting - Clinical trials for Acne Keloidalis Nuchae

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Start date: October 26, 2022
Phase: Phase 3
Study type: Interventional

Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the advantage of being the only high potency topical steroid-retinoid combination approved by the FDA with dermatologic indication. Researchers are proposing the off-labeled use of Duobrii for the management of early-mild AKN. The research team hypothesizes that subjects will experience significant clinical improvement in lesion counts. Patients will be followed with visits scheduled at baseline, 4 weeks, 8 weeks, and 12 weeks. During these in-clinic visits, there will be surveys regarding the severity of AKN symptoms, photographs, and clinical assessments.